| 2026-08-03 | Press release | Crinetics Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update |
| 2026-07-06 | Press release | Vertex to Acquire Crinetics Pharmaceuticals |
| 2026-06-30 | Press release | Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 |
| 2026-06-30 | Press release | Crinetics Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 4, 2026 |
| 2026-06-14 | Press release | Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromega |
| 2026-06-14 | Press release | Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Present |
| 2026-06-14 | Press release | Crinetics Presents Long Term Data at ENDO 2026 Confirming PALSONIFY™ (paltusotine) Provides Durable, Consistent Acromega |
| 2026-06-14 | Press release | Crinetics Presents Full Results From Phase 2 Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH) in Oral Present |
| 2026-06-02 | Press release | Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations |
| 2026-06-02 | Press release | Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Co |
| 2026-06-02 | Press release | Crinetics’ Paradigm-Shifting Portfolio and Pipeline on Display at ENDO 2026 with Six Presentations |
| 2026-05-22 | Press release | Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 |
| 2026-05-22 | Press release | Crinetics Pharmaceuticals to Participate in Jefferies Global Healthcare Conference 2026 |
| 2026-05-07 | Press release | Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-07 | Press release | Crinetics Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Business Update |
| 2026-05-07 | Earnings deck | Presentation
of Q1 2026, PDF file, (opens in new window) |
| 2026-05-07 | Press release | Press Release
of Q1 2026, PDF file, (opens in new window) |
| 2026-04-27 | Press release | Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Ac |
| 2026-04-27 | Press release | Crinetics Pharmaceuticals Announces the European Commission Approval of PALSONIFY® (Paltusotine) for the Treatment of Ac |
| 2026-04-08 | Press release | Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-04-08 | Press release | Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 |
| 2026-03-26 | Press release | Crinetics Pharmaceuticals Announces Submission of Marketing Authorization Application in Brazil for Palsonify™ (Paltusot |
| 2026-03-01 | Presentation | Crinetics to Participate in TD Cowen 46 Annual Health Care Conference |
| 2026-02-26 | Press release | Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update |
| 2026-02-26 | Press release | Press Release |
| 2026-02-26 | Earnings deck | Presentation |
| 2026-02-05 | Press release | Crinetics Pharmaceuticals to Participate in Two Upcoming Investor Conferences in March |
| 2026-01-26 | Press release | Crinetics Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026 |
| 2026-01-22 | Press release | Crinetics Initiates Phase 2/3 Pediatric Trial Evaluating Atumelnant in Congenital Adrenal Hyperplasia (CAH) |
| 2026-01-13 | Presentation | Presentation |
| 2026-01-12 | Press release | Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) |
| 2026-01-06 | Press release | Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock |
| 2026-01-05 | Press release | Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock |
| 2026-01-05 | Press release | Crinetics Announces Strong PALSONIFY Launch Execution and Positive Results for Concurrent Androstenedione Lowering and G |
| 2026-01-04 | Press release | Crinetics Pharmaceuticals to Provide PALSONIFY Business Update and Announce Topline Results from Fourth Cohort of Phase |
| 2026-01-04 | Presentation | Crinetics Pharmaceuticals, Inc. Corporate Update |
| 2025-11-06 | Earnings deck | Presentation |
| 2025-09-25 | Presentation | Presentation |
| 2025-08-07 | Earnings deck | Presentation |
| 2025-06-26 | Presentation | Presentation |